| Abstract | Tumor necrosis factor alpha (TNFalpha)-blocking agents have been used increasingly in the treatment of severe refractory juvenile idiopathic arthritis (JIA). However, some patients have been forced to discontinue these agents because of the lack of efficacy or adverse events. In these situations, cases of switching from one TNF-blocking agent to another are reported in rheumatoid arthritis, but there are few cases in JIA. This report documents the case of a patient with JIA who improved following a switch from etanercept to infliximab. |
| Authors | Yasuhito Nerome, Hiroyuki Imanaka, Yukiko Nonaka, Syuji Takei
(Affiliation: Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan. nerome at m.kufm.kagoshima-u.ac.jp)
|
| Journal | Modern rheumatology / the Japan Rheumatism Association
(Mod Rheumatol)
Vol. 17
Issue 6
Pg. 526-8
( 2007)
ISSN: 1439-7595 Japan |
| PMID | 18084710
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- infliximab
- TNFR-Fc fusion protein
- Prednisolone
- Methotrexate
|
| Topics |
- Adolescent
- Antibodies, Monoclonal
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Juvenile Rheumatoid
(drug therapy, pathology, physiopathology)
- Drug Administration Schedule
- Drug Resistance, Multiple
- Drug Therapy, Combination
- Female
- Humans
- Immunoglobulin G
(therapeutic use)
- Joints
(drug effects, pathology)
- Magnetic Resonance Imaging
- Methotrexate
(therapeutic use)
- Prednisolone
(therapeutic use)
- Receptors, Tumor Necrosis Factor
(therapeutic use)
|
